Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims provided align closely with the supplied FDA label text for AVAPRO’s hypertension indication and related cardiovascular risk reduction statements, with no direct label contradictions identified in the supplied snippets.
Category Scores
Accurate Statements
Irbesartan (Avapro) is a medication used to treat high blood pressure.
Label: “AVAPRO is indicated for the treatment of hypertension, to lower blood pressure.” (1.1 Hypertension)
AVAPRO is indicated for the treatment of hypertension, to lower blood pressure and reduce the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction.
Label: “AVAPRO is indicated for the treatment of hypertension, to lower blood pressure.” and “Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction.” (1.1 Hypertension)
Unsupported Statements
Irbesartan belongs to the class of drugs called angiotensin II receptor blockers (ARBs).
The supplied label excerpt describes irbesartan as an “angiotensin II receptor (AT1 subtype) antagonist” but does not explicitly state the term “ARB.”
Irbesartan functions by blocking the action of angiotensin II.
The mechanism section states it blocks angiotensin II’s vasoconstrictor and aldosterone-secreting effects via AT1 receptor binding, but the provided snippet does not exactly phrase this as “functions by blocking the action of angiotensin II.”
Blocking angiotensin II allows blood vessels to relax.
The mechanism excerpt discusses blockade of vasoconstrictor effects, but “allows blood vessels to relax” is not explicitly stated in the provided label text.
Relaxing blood vessels lowers blood pressure.
The label excerpt supports blood pressure reduction, but the specific causal phrasing “relaxing blood vessels lowers blood pressure” is not explicitly stated.
The patent protection for Irbesartan has expired in major markets... Specific patent expiry dates can vary by country... Multiple pharmaceutical companies manufacture and market generic versions...
Patent/generic market availability information is not included in the supplied prescribing information excerpts.
Common side effects of Irbesartan include dizziness... fatigue... a stuffy nose.
The supplied label excerpts do not list these adverse reactions or side effects.
More serious but less common risks of Irbesartan can include kidney problems.
The supplied excerpts describe “Impaired Renal Function” and risk of acute renal failure/death in certain patients, but “more serious but less common risks” is not explicitly supported by the provided text.
Kidney problems are particularly a risk for individuals with pre-existing kidney disease.
The label excerpt identifies particular risk for patients with chronic kidney disease, but the claim’s phrasing (“pre-existing kidney disease”) is broader than the specific label examples provided.
The manufacturing cost of Irbesartan (Avapro) is not publicly disclosed by Sanofi, the drug's manufacturer.
No manufacturing-cost or disclosure statements appear in the supplied prescribing information.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The label excerpt also includes an additional indication (diabetic nephropathy in type 2 diabetes) that is not mentioned in the AI claim set.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The only explicitly label-supported claims in the provided AI text concern hypertension indication and cardiovascular risk reduction. Other non-label market/patent, adverse effect frequency, and manufacturing-cost claims are not part of the hypertension indication text and are not evaluated as label-confirmed; no direct label contradictions are present in the supplied excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements (e.g., ARB terminology, mechanism phrasing, specific side effects and market/patent/manufacturing-cost details) are not explicitly supported by the supplied label excerpts.
Suggested Improvement
Limit claims to language directly present in the provided label sections (e.g., hypertension indication and cardiovascular event risk reduction in 1.1) or include only label-exact phrasing/mechanism and adverse reaction content from the relevant sections not included in the prompt.